

**New York State  
Medicaid Evidence Based Benefit Review Advisory Committee Meeting  
Agenda**

The Evidence Based Benefit Review Advisory Committee (EBBRAC) will meet on December 15, 2016 from 10:00 am to 3:30 pm in Meeting Room 1, Concourse, Empire State Plaza, Albany, New York.

**Agenda Items**

The Department of Health (Department) has requested that the EBBRAC review the current scientific research/evidence on the topics listed below and make a recommendation regarding Medicaid coverage of the proposed technology, service or drug:

- **Implantable Infusion Pumps for Non-Cancer Pain**

Implantable infusion pumps are battery powered devices that are surgically implanted to provide continuous drug delivery for pain management. The pump, which has a fluid reservoir, is placed under the skin in the abdomen. The catheter is inserted into the intrathecal or epidural space of the spine, tunneled under the skin, and connected to the pump. The drug is delivered to the spinal cord where pain signals travel, interrupting pain signals before they reach the brain.

Coverage of implantable infusion pumps for long-term, continuous delivery of opioid drugs is currently limited to only those patients with intractable cancer pain. The Committee will review the evidence presented and make a recommendation regarding expanding coverage of implantable infusion pumps for long-term, continuous delivery of opioid drugs to patients with pain not related to a cancer diagnosis.

- **BELVIQ®**

BELVIQ® (lorcaserin HCl) is a selective serotonin 2C (5-HT<sub>2C</sub>) receptor agonist that is believed to work in the brain to promote satiety. The drug is available for use in the chronic weight management of certain obese or overweight adults as an adjunct to a reduced calorie diet and increased physical activity.

Pursuant to regulations at 18 NYCRR Section 505.3(g), Medicaid does not cover drugs which have weight reduction as their sole clinical use. The Committee will review the evidence presented and make a recommendation regarding coverage of BELVIQ®.

- **Digital Breast Tomosynthesis**

Digital breast tomosynthesis is a type of mammogram that produces images of the breast in both two (2) and three (3) dimensions. During a digital breast tomosynthesis mammogram, the breast is positioned and compressed in the same way as for a digital mammogram and the breast is imaged by a series of low dose x-ray exposures. The images generate a standard two-dimensional (2-D) view and a series of images that provide information in three (3) dimensions of each breast. Digital breast tomosynthesis can be used for screening or diagnostic mammography.

Medicaid currently covers breast screening and diagnostic technologies including mammography, ultrasound and magnetic resonance imaging (MRI).

Submitted evidence on these topics can be found at the following link:

[http://www.health.ny.gov/health\\_care/medicaid/redesign/basic\\_benefit\\_ebdsp.htm](http://www.health.ny.gov/health_care/medicaid/redesign/basic_benefit_ebdsp.htm)

The Department’s systematic evidence-based assessments on these topics are provided in the announcement under Meeting Materials.

**Agenda Timeline** (subject to change based on meeting proceedings)

10:00 - 10:15	Welcome and Introductions
10:15 - 10:45	Review of EBBRAC Legislation and Guiding Principles
10:45 - 11:15	DOH Updates
11:15 - 12:30	Public Presentation Period
12:30 - 3:15	Executive Session Evidence Review, Committee Discussion, Recommendations
3:15 - 3:30	Final Comments and Adjournment

**Public Presentations**

Public presentations are oral and limited to the topics on the agenda. Presentations are limited to 2 minutes and the total public presentation period will not exceed seventy five (75) minutes. The Department reserves the right to limit the number of interested parties providing public presentations in order to meet timelines and accomplish meeting objectives.

Interested parties must notify the Department of Health by December 1, 2016 of their request to address the EBBRAC in person during the public presentation period. Requests may be made by e-mailing [EBBRAC@health.ny.gov](mailto:EBBRAC@health.ny.gov). Please include "EBBRAC Speaker Request" in the subject line of your email and complete the information in the template at the attached link.

[www.health.ny.gov/health\\_care/medicaid/ebbrac/docs/public\\_notifi\\_presentat\\_form.pdf](http://www.health.ny.gov/health_care/medicaid/ebbrac/docs/public_notifi_presentat_form.pdf)

All parties wishing to present must provide a written statement summarizing the key points. Written statements may not exceed two (2) pages in length. All written statements must be received in an electronic format by December 1, 2016.